This virtual APS meeting in collaboration with the Centre for Doctoral Training in Transformative Pharmaceutical Technologies, (University of Nottingham, University College London and Synthesis and Solid State Pharmaceutical Centre, University of Limerick) aims to provide an insight into the development of new medicines with information provided on the formulation, toxicology and clinical studies required to progress a new molecule to early clinical studies.
The presentations are given by leading practitioners from major companies.
Dr Maria Marlow is a pharmacist with a PhD in Drug Delivery, with subsequent post-doctoral research in tissue engineering at the Massachusetts Institute of Technology. She also has 18 years industrial drug delivery experience, notably working on AstraZeneca’s metered dose inhaler SYMBICORT. Her industrial career includes scientific and line manager roles from 1996, leading multi-disciplinary teams in early formulation and product development. In 2012, she was appointed as an Associate Professor in Formulation Science and Pharmaceutical Materials in the School of Pharmacy, University of Nottingham. Her research is focused on developing drug delivery systems, in collaboration with clinicians that address an unmet clinical need. Her current research projects focus on using injectable hydrogels (including supramolecular hydrogels), nanoparticles and microneedles to deliver small molecules, proteins or peptides for the treatment of cancer (skin, ovarian and brain tumours), HIV and pain. The research involves the physicochemical characterisation of these deliver systems to allow the prediction of their in vivo performance. Currently Maria is the deputy director of the EPSRC CDT in Advanced Therapeutics and Nanomedicine and the Training director for the EPSRC CDT in Transformative Pharmaceutical Technologies. She is also a committee member of the Academy of Pharmaceutical Sciences Parenteral Focus group.
Dr John Wahlich-Chair
John has been a consultant in the pharmaceutical sciences for over 6 years. Prior to that he had over 40 years’ experience in product development in the pharmaceutical industry. John is a chemist by training (PhD from Nottingham School of Pharmacy) and has analytical and formulation expertise gained from leadership roles in product line extensions, physical properties and early stage development in GlaxoSmithKline and other major pharmaceutical companies. He is a former vice president of the APS and is now a member of the APS Advisory Board.
Paul is a Senior Project Toxicologist within the AstraZeneca’s Regulatory Safety group in Cambridge where his primary role is to oversee the non-clinical development of respiratory based products. Paul has worked in the pharmaceutical industry for over 27 years (GSK and AZ) with the majority of that time within Safety Assessment where he has also held roles of Clinical Pathologist and Study Director. Paul has oversight in the design and conduct of appropriate regulatory toxicology packages to support internal and external asset development in accordance with appropriate guidelines. In addition to the development of pharmaceutical ingredients, Paul also gained experience in the development and safety evaluation of novel dry powder inhalation platforms.
For a 3 year period, Paul worked within the Drug Delivery group (GSK) to support the identification, evaluation and development (CMC and safety) of novel drug delivery platforms (for example long acting injections and Microneedles) to meet portfolio needs and to improve parameters such as patient compliance, delivery efficiency and reduced toxicity.
Mei is a Senior Principal Scientist within the Drug Product Design group at Pfizer. She has over 10 years of formulation development experience across all the different stages of drug product development, from pre-clinical to commercialisation. She is a pharmacist by training and has a Pharmaceutics PhD from the School of Pharmacy, University of London.
Peter read Pharmaceutical Sciences at the University of Nottingham, UK, gaining his PhD in 1993. He has over 25 years’ experience in the Pharmaceutical Industry and joined Quotient Sciences in 2007. Peter has been instrumental in developing innovative and adaptive approaches to integrate pharmaceutical development and clinical testing in early research. He was appointed to the position of CSO in March 2013 where he now has responsibility for the scientific strategy and leadership at Quotient. Peter has previously served as a committee member for the UK Controlled Release Society and APS Biopharmaceutics focus group and in 2013 set up a GastroPlus user group with industry colleagues as a discussion forum for PBPK modelling and simulation science. In 2010, Peter was named one of PharmaVOICE’s 100 most inspiring people in the life-sciences industry. He was appointed as an Honorary Professor in Pharmaceutical Sciences at Nottingham University in August 2015.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.